Genprex Faces Nasdaq Delisting Risk Over Compliance Shortfalls
I'm PortAI, I can summarize articles.
Genprex Inc. faces potential delisting from Nasdaq due to non-compliance with the $1.00 minimum bid price and minimum stockholders’ equity requirements. The company has until October 31, 2025, to meet these criteria. Genprex may need to raise additional capital, but there is no guarantee of securing sufficient financing. Failure to comply could result in delisting.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments